GlassScriptPhysician profile
Colleen Silva
NPI 1841797735
$4,432.36
in general payments reported to CMS, 2019-2025
23 companies · $1,472 in 2025
The $1,472 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.19 · 2020: $76.45 · 2021: $74.31 · 2022: $445 · 2023: $839 · 2024: $1,427 · 2025: $1,472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,579 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,579.38 |
| Education | $159.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $730.42 | 2021-2025 | Ilumya |
| Lilly USA, LLC | $660.15 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $647.64 | 2022-2025 | Bimzelx |
| Abbvie INC. | $365.55 | 2020-2025 | |
| Pfizer INC. | $296.53 | 2022-2025 | |
| Janssen Biotech, INC. | $285.32 | 2023-2025 | Tremfya, Simponi, Simponi Aria |
| Journey Medical Corporation | $200.93 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $195.86 | 2019-2025 | Dupixent |
| Organon LLC | $186.78 | 2024-2025 | Hadlima |
| Sanofi-Aventis U.S. LLC | $161.95 | 2022-2024 | |
| Genzyme Corporation | $138.91 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $104.54 | 2023-2025 | |
| Amgen INC. | $94.32 | 2024-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $69.17 | 2024 | Vtama |
| Organogenesis INC. | $63.17 | 2023-2024 | Puraply |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $43.68 | 2024 | Poteligeo |
| E.R. Squibb & Sons, L.L.C. | $42.80 | 2023-2024 | Sotyktu |
| Paratek Pharmaceuticals, INC. | $29.38 | 2025 | Nuzyra |
| Incyte Corporation | $25.12 | 2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.07 | 2024 | Cyltezo |
| Fresenius Kabi USA, LLC | $24.90 | 2023 | |
| Galderma Laboratories, L.P. | $24.06 | 2025 | Nemluvio |
| Smith+Nephew, INC. | $16.11 | 2025 | Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.